MS Therapy – Gilenya (Fingolimod) Oral Medication

Name: Gilenya (Fingolimod)

Type: Oral Medication
Approved: 2010
Approved For: Reducing the frequency of MS flare-ups (relapses) in patients with Relapsing Remitting Multiple Sclerosis (RRMS) as well as reducing the long term disability effects of MS.
Reported Relapse Reduction Rate: 54% Compared to placebo
Recommended Dosage: 0.5mg orally once daily (with or without food)
Schedule: Daily
Storage: Gilenya capsules should be stored at 77F (25C)
Support Team: Go Program – 1-800-445-3692 – Offers information on paying for medication, information about the first day on medication, forms to start Gilenya, reminders, motivation, and support.

Read more

Liberation Therapy – CCSVI Theory Challenged

In 2009 Dr. Paolo Zamboni of Italy went public with his theory that Multiple Sclerosis was not an autoimmune disease but in fact a vascular disease that causes obstructed blood flow in the veins that drain the central nervous system. He developed this theory after his wife was diagnosed with Multiple Sclerosis in the early 90’s, a problem he set out to solve.

Read more